Impact of nonsteroidal anti-inflammatory drugs on the efficacy,toxicity and prognosis of immunotherapy in non-small lung cancer
Objective To explore the impact of nonsteroidal anti-inflammatory drugs(NSAIDs)on clinical effica-cy,toxicity and prognosis in non-small cell lung cancer after immunotherapy.Methods The clinical data of patients with advanced non-small cell lung cancer who received immunotherapy in our hospital from January 2019 to March 2021 were retrospectively analyzed.Patients were divided into NSAIDs group(n=79)and Non-NSAIDs group(n=86)according to whether NSAIDS were used within 42 days before or after immunotherapy.Objective response rate(ORR)and disease control rate(DCR)were compared between the two groups.Kaplan-Meier method was used to calculate overall survival(OS)and progression-free survival(PFS).Univariate and multivariate analyses of prognostic factors were performed by COX proportional hazard regression model.Results The ORR of patients in NSAIDs group was higher than that patients in Non-NSAIDs group(73.40％vs 58.10％,P=0.039),and there was no difference in DCR between the two groups(96.20％vs 93.00％,P=0.369).There was no difference in the incidence of grade 3 or higher immune-related adverse events between the two groups(2.50％,vs 4.70％,P=0.683).The median PFS(16 months vs 15 months,P=0.021)and OS(25 months vs 21 months,P=0.027)of patients in NSAIDs group were higher than those in Non-NSAIDs group.Both univariate and multivariate analyses suggested that the use of NSAIDs were factors influencing the OS and PFS of patients with advanced non-small cell lung cancer who received immunotherapy.Conclusion Among patients with non-small cell lung cancer receiving immunotherapy,patients using NSAIDs had a higher objective response rate.NSAIDs is good prognostic factors in patients with non-small cell lung cancer after immunotherapy.
万方数据
维普
